Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 10, 2016, Pages 1674-1683

  Kumada, Hiromitsu ^a   Mochida, Satoshi ^b   Suzuki, Fumitaka ^a   Chayama, Kazuaki ^c   Karino, Yoshiyasu ^d   Nakamura, Keisuke ^e   Fujimoto, Go ^e   Howe, Anita Y M ^f   Ludmerer, Steve W ^f   Mobashery, Niloufar ^f  

^a TORANOMON HOSPITAL   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d Sapporo Kosei General Hospital   (Japan)

^e Merck Sharp Dohm Res Labs Japan   (Japan)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

hepatitis C virus; Japan; peginterferon; ribavirin; vaniprevir

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VANIPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; INDOLE DERIVATIVE; MACROGOL DERIVATIVE; MK-7009; RECOMBINANT PROTEIN;

ADULT; ADVERSE OUTCOME; AGED; ANKLE FRACTURE; ANTIVIRAL THERAPY; APPENDICITIS; ARTICLE; ASPIRATION PNEUMONIA; BACKACHE; CHILL; COMPRESSION FRACTURE; CONTUSION; DEPRESSION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GENETIC VARIABILITY; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN CELL; JAPANESE (PEOPLE); LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; OPEN STUDY; PALLOR; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RIB FRACTURE; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; VOMITING; ANTIVIRAL RESISTANCE; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDOLES; INTERFERON-ALPHA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 85002156773     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13328     Document Type: Article

References (11)

1. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53: 39–43.
2. Mizokami M, Yokosuka O, Takehara T et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect. Dis. 2015; 15: 645–53.
3. Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083–91.
4. McCauley JA, McIntyre CJ, Rudd MT et al. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J. Med. Chem. 2010; 53: 2443–63.
5. Liverton NJ, Carroll SS, DiMuzio J et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother. 2010; 54: 305–311.
6. Olsen DB, Davies M-E, Handt L et al. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob. Agents Chemother. 2011; 55: 937–9.
7. Lawitz E, Sulkowski M, Jacobson I et al. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Res. 2013; 99: 214–20.
8. Hayashi N, Nakamuta M, Takehara T et al. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study. J. Gastroenterol. 2015. DOI: http://dx.doi.org/10.1007/s00535-015-1120-x.
9. Lawitz E, Rodriguez-Torres M, Stoehr A et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J. Hepatol. 2013; 59: 11–7.
10. Rodriguez-Torres M, Stoehr A, Gane EJ et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clin. Gastroenterol. Hepatol. 2014; 12 1029–37.e5.
11. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection: a 2014 update for genotype 1. Hepatol. Res. 2014; 44 (suppl S1): 59–70.